8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Apr 1, 2026·SEC
Material company update
Mar 9, 2026·SEC
Design Therapeutics, Inc.(DSGN)Earnings, Financials & Key Ratios
DSGN•NASDAQ
$14.55
$909M mkt cap·Price updated May 6, 2026
AboutDesign Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.Show more
- Revenue$0
- EBITDA-$79M-27.6%
- Net Income-$70M-40.7%
- EPS (Diluted)-1.22-38.6%
- ROE-30.7%-60.9%
- ROIC-28.51%-46.7%
- Debt/Equity0.00-68.5%
DSGN Key Insights
Design Therapeutics, Inc. (DSGN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 93 (top 7%)
✗Weaknesses
- ✗Profits declining 53.2% over 5 years
- ✗Weak Piotroski F-Score: 2/9
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
DSGN Price & Volume
Design Therapeutics, Inc. (DSGN) stock price & volume — 10-year historical chart
Loading chart...
DSGN Growth Metrics
Design Therapeutics, Inc. (DSGN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-24.05%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-21.21%
Return on Capital
10 Years-29.37%
5 Years-24.04%
3 Years-28.08%
Last Year-34.79%
DSGN Recent Earnings
Design Therapeutics, Inc. (DSGN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 10/12 qtrs (83%)
Q2 2026Latest
Apr 28, 2026EPS
$0.29
Est $0.36
+19.4%
Revenue
—
Q2 2026
Mar 9, 2026EPS
$0.27
Est $0.38
+28.9%
Revenue
—
Q4 2025
Nov 5, 2025EPS
$0.30
Est $0.34
+11.8%
Revenue
—
Q3 2025
Aug 7, 2025EPS
$0.34
Est $0.32
-6.3%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $0.29vs $0.36+19.4% | — |
| Q2 2026 | Mar 9, 2026 | $0.27vs $0.38+28.9% | — |
| Q4 2025 | Nov 5, 2025 | $0.30vs $0.34+11.8% | — |
| Q3 2025 | Aug 7, 2025 | $0.34vs $0.32-6.3% | — |
Based on last 12 quarters of dataView full earnings history →
DSGN Peer Comparison
Design Therapeutics, Inc. (DSGN) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 FULC | 384.73M | 7.11 | -6.03 | -100% | -27.8% | 0.02 | ||
 EXAS | 20.02B | 104.91 | -95.37 | 17.69% | -6.4% | -8.66% | 1.05 | |
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 ARQT | 3.02B | 24.17 | -185.92 | 91.34% | -0.57% | -1.41% | 0.03 | |
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 | |
 EDIT | 310.73M | 3.18 | -1.76 | -100% | -5.23% | 0.66 | ||
 CRSP | 5.31B | 55.08 | -8.51 | -89.97% | -138.57% | -30.88% | 0.21 | |
 NTLA | 1.61B | 13.85 | -3.64 | -100% | -61.47% | 0.14 |
Compare DSGN vs Peers
Design Therapeutics, Inc. (DSGN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DSGN Income Statement
Design Therapeutics, Inc. (DSGN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 834 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | -100% | - | - | - | - | - | - |
| Cost of Goods Sold | 1.65K | 5K | 0 | 466K | 537K | 596K | 622K | 0 |
| COGS % of Revenue | 198.32% | - | - | - | - | - | - | - |
| Gross Profit | -820▲ 0% | -5K▼ 509.8% | 0▲ 100.0% | -466K▲ 0% | -537K▼ 15.2% | -596K▼ 11.0% | -622K▼ 4.4% | 0▲ 0% |
| Gross Margin % | -98.32% | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | -509.76% | 100% | - | -15.24% | -10.99% | -4.36% | - |
| Operating Expenses | 1.91M | 8.55M | 35.83M | 67.13M | 77.65M | 61.79M | 78.84M | 78.75M |
| OpEx % of Revenue | 228776.98% | - | - | - | - | - | - | - |
| Selling, General & Admin | 1.09M | 2.5M | 11.05M | 18.98M | 21.13M | 18.03M | 20.34M | 20.62M |
| SG&A % of Revenue | 130455.64% | - | - | - | - | - | - | - |
| Research & Development | 1.65M | 6.06M | 24.78M | 48.61M | 57.06M | 44.35M | 59.13M | 58.13M |
| R&D % of Revenue | 198321.34% | - | - | - | - | - | - | - |
| Other Operating Expenses | -834K | 0 | 0 | -466K | -537K | -596K | -622K | -152K |
| Operating Income | -1.91M▲ 0% | -8.56M▼ 348.4% | -35.83M▼ 318.8% | -67.59M▼ 88.6% | -78.19M▼ 15.7% | -62.38M▲ 20.2% | -79.47M▼ 27.4% | -78.75M▲ 0% |
| Operating Margin % | -228776.98% | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -348.43% | -318.78% | -88.64% | -15.68% | 20.22% | -27.39% | - |
| EBITDA | 0 | -8.55M | -35.7M | -67.13M | -77.65M | -61.79M | -78.84M | -78.29M |
| EBITDA Margin % | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | - | -317.52% | -88.02% | -15.68% | 20.43% | -27.61% | -15.49% |
| D&A (Non-Cash Add-back) | 1.91M | 5K | 129K | 466K | 537K | 596K | 622K | 463K |
| EBIT | -2.05M | -8.28M | -35.83M | -63.31M | -66.86M | -49.59M | -79.47M | -54.25M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 12.79M | 9.68M | 6.97M |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 12.79M | 9.68M | 9.04M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -139K | 276K | 298K | 4.29M | 11.33M | 12.79M | 9.68M | 9.04M |
| Pretax Income | -2.05M▲ 0% | -8.28M▼ 304.5% | -35.53M▼ 329.1% | -63.31M▼ 78.2% | -66.86M▼ 5.6% | -49.59M▲ 25.8% | -69.79M▼ 40.7% | -69.71M▲ 0% |
| Pretax Margin % | -245443.65% | - | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -2.05M▲ 0% | -8.28M▼ 304.5% | -35.53M▼ 329.1% | -63.31M▼ 78.2% | -66.86M▼ 5.6% | -49.59M▲ 25.8% | -69.79M▼ 40.7% | -69.71M▲ 0% |
| Net Margin % | -245443.65% | - | - | - | - | - | - | - |
| Net Income Growth % | - | -304.49% | -329.14% | -78.17% | -5.61% | 25.84% | -40.74% | -24.05% |
| Net Income (Continuing) | -2.05M | -8.28M | -35.53M | -63.31M | -66.86M | -49.59M | -69.79M | -69.71M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.08▲ 0% | -0.30▼ 298.4% | -0.77▼ 156.7% | -1.14▼ 48.1% | -1.19▼ 4.4% | -0.88▲ 26.1% | -1.22▼ 38.6% | -1.13▲ 0% |
| EPS Growth % | - | -298.41% | -156.67% | -48.05% | -4.39% | 26.05% | -38.64% | -21.21% |
| EPS (Basic) | -0.08 | -0.30 | -0.77 | -1.14 | -1.19 | -0.88 | -1.22 | - |
| Diluted Shares Outstanding | 27.19M | 27.19M | 45.94M | 55.71M | 55.98M | 56.59M | 57.33M | 61.43M |
| Basic Shares Outstanding | 27.19M | 27.19M | 45.94M | 55.71M | 55.98M | 56.59M | 57.33M | 61.43M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
DSGN Balance Sheet
Design Therapeutics, Inc. (DSGN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 90K | 36.23M | 385.44M | 335.12M | 284.58M | 248.04M | 223.78M | 227.05M |
| Cash & Short-Term Investments | 77K | 36.09M | 384.06M | 330.39M | 281.8M | 245.48M | 219.84M | 222.82M |
| Cash Only | 77K | 2.38M | 298.57M | 26.5M | 21.2M | 22.56M | 16.86M | 12.77M |
| Short-Term Investments | 0 | 33.71M | 85.5M | 303.89M | 260.6M | 222.91M | 202.99M | 210.05M |
| Accounts Receivable | 0 | 10K | 110K | 1.11M | 1.43M | 1.26M | 1.68M | 1.82M |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 8K | 25K | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 0 | 283K | 5.12M | 6.02M | 5.06M | 4.05M | 2.42M | 3.39M |
| Property, Plant & Equipment | 0 | 71K | 5.12M | 5.56M | 4.63M | 3.63M | 2.42M | 3.39M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 212K | 0 | 459K | 430K | 427K | 0 | 0 |
| Total Assets | 90K▲ 0% | 36.52M▲ 40473.3% | 390.56M▲ 969.6% | 341.14M▼ 12.7% | 289.64M▼ 15.1% | 252.09M▼ 13.0% | 226.2M▼ 10.3% | 230.44M▲ 0% |
| Asset Turnover | 0.01x | - | - | - | - | - | - | 0.00x |
| Asset Growth % | - | 40473.33% | 969.55% | -12.65% | -15.09% | -12.96% | -10.27% | -49.61% |
| Total Current Liabilities | 3.73M | 2.33M | 5.28M | 10.78M | 9.62M | 8.46M | 13.05M | 10.19M |
| Accounts Payable | 2.48M | 1.4M | 1.62M | 3.02M | 1.94M | 2.19M | 2.31M | 2.28M |
| Days Payables Outstanding | 547.06K | 102.13K | - | 2.37K | 1.32K | 1.34K | 1.36K | - |
| Short-Term Debt | 695K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 201K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 112K | 565K | 2.15M | 3.54M | 4.03M | 0 | 10.74M | 2.33M |
| Current Ratio | 0.02x | 15.55x | 72.96x | 31.10x | 29.58x | 29.31x | 17.14x | 17.14x |
| Quick Ratio | 0.02x | 15.55x | 72.96x | 31.10x | 29.58x | 29.31x | 17.14x | 17.14x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 1K | 45.5M | 3.14M | 3.05M | 2.33M | 1.53M | 645K | 2.2M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 645K | 0 |
| Capital Lease Obligations | 0 | 0 | 3.14M | 3.05M | 2.33M | 1.53M | 0 | 4.82M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 1K | 45.5M | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 3.73M | 47.83M | 8.43M | 13.83M | 11.96M | 10M | 13.7M | 12.39M |
| Total Debt | 695K | 0 | 3.63M | 3.69M | 3.05M | 2.33M | 645K | 2.73M |
| Net Debt | 618K | -2.38M | -294.94M | -22.81M | -18.15M | -20.23M | -16.21M | -10.04M |
| Debt / Equity | - | - | 0.01x | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x |
| Debt / EBITDA | - | - | - | - | - | - | - | -0.03x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | 0.13x |
| Interest Coverage | - | - | - | - | - | - | - | - |
| Total Equity | -3.64M▲ 0% | -11.31M▼ 210.7% | 382.13M▲ 3477.2% | 327.31M▼ 14.3% | 277.69M▼ 15.2% | 242.1M▼ 12.8% | 212.5M▼ 12.2% | 218.05M▲ 0% |
| Equity Growth % | - | -210.68% | 3477.2% | -14.35% | -15.16% | -12.82% | -12.22% | -55.89% |
| Book Value per Share | -0.13 | -0.42 | 8.32 | 5.88 | 4.96 | 4.28 | 3.71 | 3.55 |
| Total Shareholders' Equity | -3.64M | -11.31M | 382.13M | 327.31M | 277.69M | 242.1M | 212.5M | 218.05M |
| Common Stock | 1K | 1K | 6K | 6K | 6K | 6K | 6K | 6K |
| Retained Earnings | -3.64M | -11.92M | -47.46M | -110.76M | -177.63M | -227.21M | -297.01M | -314.64M |
| Treasury Stock | 0 | -451K | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 156K | -244K | -3.36M | 62K | 475K | 403K | -268K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DSGN Cash Flow Statement
Design Therapeutics, Inc. (DSGN) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -139K | -8.67M | -29.38M | -51.32M | -58.56M | -43.1M | -54.36M | -54.36M |
| Operating CF Margin % | -16666.67% | - | - | - | - | - | - | - |
| Operating CF Growth % | - | -6136.69% | -238.87% | -74.68% | -14.11% | 26.39% | -26.11% | -64.41% |
| Net Income | -2.05M | -8.28M | -35.53M | -63.31M | -66.86M | -49.59M | -69.79M | -69.71M |
| Depreciation & Amortization | 0 | 5K | 129K | 406K | 537K | 596K | -2.63M | 1.02M |
| Stock-Based Compensation | 0 | 450K | 4.69M | 10.93M | 13.09M | 13.07M | 14.55M | 14.93M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 95K | -33K | -58K | -1.33M | -6.05M | -6.19M | 406K | -5.06M |
| Working Capital Changes | 1.81M | -811K | 1.4M | 1.99M | 728K | -993K | 3.11M | 4.82M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | -413K | 2.41M | 5.38M | -1.25M | -1.22M | 4.49M | 2.28M |
| Cash from Investing | 0 | -33.56M | -53.64M | -220.99M | 52.54M | 43.95M | 22.91M | 7.45M |
| Capital Expenditures | 0 | -76K | -1.54M | -918K | -256K | -340K | -193K | -121K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 52.11K | 39K | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | -52.11K | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 196K | 44.53M | 379.21M | 235K | 724K | 513K | 25.74M | 45.65M |
| Debt Issued (Net) | 196K | -200K | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 44.73M | 378.98M | 662K | 724K | 513K | 25.74M | 25.71M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 1K | 228K | -427K | 0 | 0 | 0 | 19.93M |
| Net Change in Cash | 57K▲ 0% | 2.3M▲ 3938.6% | 296.19M▲ 12766.6% | -272.07M▼ 191.9% | -5.3M▲ 98.1% | 1.36M▲ 125.7% | -5.71M▼ 518.7% | -897K▲ 0% |
| Free Cash Flow | -139K▲ 0% | -8.74M▼ 6191.4% | -30.91M▼ 253.5% | -52.23M▼ 69.0% | -58.82M▼ 12.6% | -43.45M▲ 26.1% | -54.55M▼ 25.6% | -54.12M▲ 0% |
| FCF Margin % | -16666.67% | - | - | - | - | - | - | - |
| FCF Growth % | - | -6191.37% | -253.52% | -68.96% | -12.6% | 26.13% | -25.56% | -13.53% |
| FCF per Share | -0.01 | -0.32 | -0.67 | -0.94 | -1.05 | -0.77 | -0.95 | -0.95 |
| FCF Conversion (FCF/Net Income) | 0.07x | 1.05x | 0.83x | 0.81x | 0.88x | 0.87x | 0.78x | 0.78x |
| Interest Paid | 0 | 24K | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
DSGN Key Ratios
Design Therapeutics, Inc. (DSGN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -19.16% | -17.85% | -22.1% | -19.08% | -30.7% | -33.07% |
| Return on Invested Capital (ROIC) | - | -73.12% | -25.88% | -20.79% | -19.44% | -28.51% | -28.51% |
| Debt / Equity | - | 0.01x | 0.01x | 0.01x | 0.01x | 0.00x | 0.00x |
| FCF Conversion | 1.05x | 0.83x | 0.81x | 0.88x | 0.87x | 0.78x | 0.78x |
| Revenue Growth | -100% | - | - | - | - | - | - |
DSGN SEC Filings & Documents
Design Therapeutics, Inc. (DSGN) SEC filings — annual & quarterly reports (10-K, 10-Q)
DSGN Frequently Asked Questions
Design Therapeutics, Inc. (DSGN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Design Therapeutics, Inc. (DSGN) grew revenue by 0.0% over the past year. Growth has been modest.
Design Therapeutics, Inc. (DSGN) reported a net loss of $69.7M for fiscal year 2025.
Dividend & Returns
Design Therapeutics, Inc. (DSGN) has a return on equity (ROE) of -30.7%. Negative ROE indicates the company is unprofitable.
Design Therapeutics, Inc. (DSGN) had negative free cash flow of $54.1M in fiscal year 2025, likely due to heavy capital investments.
Explore More DSGN
Design Therapeutics, Inc. (DSGN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates